United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

Core Insights - United Therapeutics Corporation reported record financial results for Q3 2025, with total revenues reaching $799.5 million, a 7% increase from $748.9 million in Q3 2024 [1] Financial Performance - Total revenues for Q3 2025 grew by 7% year-over-year, indicating strong performance in key products [1] - Key products contributing to revenue growth include Tyvaso® and Orenitram® [1]